Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

February 12, 2016

Howard Solomon, Chairman and Chief Executive Officer of Forest, said, "We are pleased to have entered into this second major collaboration with Almirall, one of the premier innovators in the respiratory field. This agreement represents an exciting extension of the strong collaboration established with aclidinium bromide for COPD three years ago between Forest and Almirall and which will be completing Phase III studies in 2010. LAS100977 has shown very encouraging results in the completed Phase II studies, and we believe it will be a very competitive entrant in this large drug class. With the addition of LAS100977, Forest rounds out a broad COPD pipeline that was recently augmented with DAXAS? (roflumilast) and will also gain access to the larger asthma market with a once-daily inhaled corticosteroid/LABA combination.???